Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04902872 · ClinicalTrials.gov registry record · Phase 1
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Cybrexa Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 4
- Study locations
NCT04902872 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Cybrexa Therapeutics. The registered enrollment target is 130 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT04902872, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Cybrexa Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
Conditions Studied
Interventions
- DRUG CBX-12
Study Locations (4)
Texas
- NEXT Oncology - Austin
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Connecticut
- Yale Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2025-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04902872
The ClinicalTrials.gov registry entry for NCT04902872 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Cybrexa Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CBX-12 is the first listed.
NCT04902872 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04902872 about?
NCT04902872 is a clinical study titled "Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors". This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
What is the current status of trial NCT04902872?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2021-05-03. Estimated completion is 2025-06.
What conditions does trial NCT04902872 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Solid Tumor, Adult.
What interventions are being tested in trial NCT04902872?
The interventions under investigation include: CBX-12 (DRUG).
Who is sponsoring clinical trial NCT04902872?
This trial is sponsored by Cybrexa Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04902872 being conducted?
This trial has 4 study locations across Connecticut, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.